北京协和医院拥有的“一体式POCT检测15种腹泻病原体的试剂盒、检测管及检测系统”科研成果，拟进行科技成果转让，欢迎有兴趣的单位来参与洽谈转让。公示日期：自2025年12月5日----2025年12月20日止联系人：北京协和医院科研处科技成果转化办公室电话：69155708公示人：北京协和医院科研处科技成果转化办公室2025年12月5日
2025.12.05
北京协和医院2026年3月护理进修报名现已开始。请通过进修生报名系统https://cme.pumch.cn:8888/study（北京协和医院进修生管理-护理报名）进行行统一报名。报名截止时间：2026年2月13日进修报到时间：2026年3月上旬（具体时间以通知为准）进修通知单将以网站内通知邮件形式发送，请注意查收。
2025.12.04
为满足临床工作需要，北京协和医院对拟遴选的耗材进行市场调研,诚邀相关产品的厂家、代理商参与并提供相关信息资料。1.市场调研内容2.报名资格：（1）本次市场调研的耗材代理商要求为区域二级以上代理。（2）针对每种产品，代理商仅能递交单一品牌的单一产品参与调研，若发现代理商对同一产品进行多个品牌或同一品牌多种产品重复递交，则视为无效。3.报名文件要求：请按以下清单顺序整理并准备（1）《医用耗材遴选市场调研表》（点击下载：附件1）（2）代理商《营业执照》、《医疗器械经营许可证》。（3）代理商逐级授权书(授权有效期不少于6个月)。（4）代理商个人授权书及身份证的正反面复印件。（5）代理商被授权人近三个月缴纳社保证明。（6）生产厂家《营业执照》、《医疗器械生产企业许可证》。（7）生产厂家的授权书(授权有效期不少于6个月)。（8）产品医疗器械注册证/登记证/备案证。（9）产品说明书、合格证/进口产品报关单、宣传彩页。（10）近三个月内供应同级别医院的最低价格发票复印件。（11）产品技术参数文件。以上提供的所有文件材料均须真实、有效。4.报名截止时间及要求：（1）报名截止时间：2025年12月10日17:00。（2）所有报名文件均须加盖供应商公章后制成电子扫描件。其中，《医用耗材遴选市场调研表》（附件1）除扫描件外，还须同时提供可编辑的Excel表格文件。请将上述所有文件压缩为一个ZIP或RAR格式文件，发送至邮箱：lx_pumch@163.com。（3）邮件及附件命名要求：所有邮件标题与附件标题的名称必须保持一致，并严格遵循以下格式：医用耗材市场调研2025-LX-005-XX（需求序号）-XX（产品名称）-XX（公司名称）5.注意事项5.1报名文件未按要求提交或逾期的，将不予受理。5.2项目联系人：张老师；联系电话：69156697。
2025.12.04
医学博士，主治医师。2019年毕业于北京协和医学院临床医学八年制专业，获医学博士学位，同年就职于北京协和医院内科。2022年任内科总住院医师，现任风湿免疫科主治医师。曾获院级优秀住院医师、优秀内科总住院医师、优秀员工等荣誉。曾前往芝加哥大学医学院、纽约石溪大学医学院访问学习。研究方向为系统性血管炎、脊柱关节炎，以第一/共一身份发表多篇SCI/中华核心期刊，多次国际学术会议发言获奖。
2025.12.04
自即日起机构办工作进行以下调整，各岗位联系电话及邮箱详见“办事服务”：1.合同审查邮件递交：发至各纵向秘书邮箱2.办理入账邮件递交-唐颖新（69154124，tangyingxin@pumch.cn）3.结算表现场递交和领取：2025年12月4日前已递交的结算表、I期和IVD项目-胡帅亚，其余-各纵向秘书4.总结报告、分中心小结、发补资料现场递交-胡帅亚5.CRC备案、人脸录入-胡帅亚（69154114，hushuaiya@pumch.cn）6.质控预约-侯旭粲（69154231，houxucan@pumch.cn）
2025.12.04
“百年协和，一切为民”,北京协和医院是我国现代医学的引领者，全国疑难重症罕见疾病诊治中心，也是我国内分泌代谢事业的发祥地。近百年来，协和内分泌同仁赓续奋斗，努力提升我国内分泌代谢疾病的医疗和研究水平，取得了丰硕的学术成果，树立了良好的学术声誉，形成了深厚的学术影响，也为我国内分泌领域培养了一大批优秀人才。为助力医院高质量发展，促进与区域医疗中心合作交流，培养高层次内分泌领军和专业技术人才，开设协和内分泌高级（精英）人才培训班。培训时间为期3个月（2026年3月5日至6月），科室将依据每位学员的临床能力、科研基础和学习目标，采用一对一导师制，从医疗、教学、科研和管理等方面给予全方位的指导。报名条件：需符合北京协和医院进修医师报名相关要求，并且为区域医疗中心三甲医院，具有副高及以上职称的临床医师。报名流程：报名申请→教育处资质审核→科室遴选→确定录取名单→发放录取通知→院前培训→来院报到。报名网站：报名及录取具体要求详见医院网站https://cme.pumch.cn:8888/study。报名日期：2026年1月1日至2026年1月20日。
2025.12.02
NewtreatmentsmeanAIDSisseenaschronicdiseasejustlikediabetes○ChinahascomealongwayinovercominginitialstigmaoftreatingAIDSpatients○ApolyclinicaltreatmentnetworkisbeingconstructedtoprovideHIV-infectedpeoplebetterlivesAresearcherchecksCD4cellsintheCentreLaboratoryofShanghaiXuhuiCentralHospitalinShanghai.Photo:VCGIn2017,an80-year-oldHIV-positivemanunderwentsuccessfulcardiacsurgeryattheBeijing-basedPekingUniversityPeople’sHospital,undertherecommendationofProfessorLiTaisheng,theDirectoroftheInfectiousDiseasesDepartmentinthePekingUnionMedicalCollegeHospital(PUMCH).AsoneofChina’sleadingresearchersandarenownedclinicalspecialistinHIV,LitoldtheGlobalTimesthatHIV-positivepeople’slongtermsurvivalhasbecomeanimportantissueinChina,nowthatthediseasecanbecontrolledandregulatedasachronicdisease.“NowthatHIV-infectedpeople’sliveshavebeenlargelyprolonged,we’reinadilemmawithregardstothetreatmentofitscomplications,sincespecializedinfectionhospitalsarenotcapableofdoingsurgeriesandpatientswithinfectiousdiseaseshavetobetreatedinspecializedinfectionhospitals,”saidLi.FromlethaltochronicIn2017,morethan610,000HIV-positivepeoplereceivedanti-viraltreatment,comparedto171,000in2012,withacoveragerateof80.4percentandasuccessrateofabove90percent,accordingtoChina’sHealthCommission.LiannouncedproudlyataChina-FrenchmedicalseminarthatAIDShasnowbecomeachronicdiseaselikehighbloodpressureanddiabetes.AnHIVpatientcannowsurvivefordecadesifheorshekeepstakingmedication.LiworkedatPUMCHasaninternin1983andbecameadoctoratthehospitalthenextyear.InJuly1985,PUMCHacceptedChina’sfirstHIV-positivepatient.“Abatchofpatientsdiedeverycoupleofmonths,sincetherewasnomedicineforthediseaseintheworld,”Lisaid.“Ourhandsweretied.Wecouldonlywatchourpatientsdie.”Atthattime,fearofthefataldiseasewasoverwhelming.“Thefearcamefromthelackofmedicine,ignoranceofthediseaseandits100percentfatalityrate,”Liexplained.FuYan,theheadnurseatBeijingYouAnHospital,recalledthefearthathungoverthehospitalwhenthefirstAIDSpatientwasadmittedin1990.“Doctorsandnursesneverenteredthepatient’sward,andasmallwindowinthewallnexttothedoorwasusedtotakebloodsamplesandpassfoodanddailysupplies,”FusaidtotheChinaPictorial.Afterthepatientdied,apyrewasbuiltinanopenspacetoincinerateeveryitemthepatienthadused.“Theinflammablethingswerewipedwithdisinfectantfluidandtheisolatedwardwassteamedwithperaceticacid,”Furecalled.OntopoftheharshlivingconditionsfacedbyHIVpatients,medicinebackthenwashardtocomebyandexpensive.“Abottleofmedicinecostasmuchas10,000yuan($1,450)atthattime,whichwasunaffordableformostfamilies,”LitoldtheGlobalTimes.In1998,BeijingYouAnHospitalintroducedHighlyActiveAnti-RetroviralTherapy(HAART),alsoknownascocktailtherapy,acombinationofthreeormoreanti-viraldrugstorestorethedamagedimmunesystemsofHIV-positivepeopleinordertoprolongtheirlives.ThefivepatientswhomadeupthefirstgroupofHIV-positivepatientstoreceivethetherapyin1998arenowleadingnormallives.However,thetherapywasnotaccessibletoeveryoneduetoitshighpriceandthescarcityofanti-viraldrugs.LisaidthattherewasnofreemedicineforHIV-positivepeopleinChinauntil2004,whenChinastartedtoprovidefreetesting,treatmentandmedicineforthem.In2005,anationwideAIDSclinictreatmentnetworkwasestablishedandLibecameitspresident.Basedonpilottestsacrossthecountry,LidiscoveredthemosteffectivetwomedicinecombinationsthatsuitedChinesepeople’sconstitutionsandminimizedtheirsideeffects.“Overthepastdecade,IhavebeenfocusingontheeffectofthesefreemedicinesonChinesepatients,includingcombinationsandvolume,”saidLi.“Gradually,patientsrealizedthatChina’sfreemedicinehadthesameeffectsastheimportedmedicines,andbecamewillingtotakethem.”Lialsocompiledthetreatmentexperienceandplansheobtainedfromtheresearchintobooks,distributingtocountiesacrossthecountryviathenetwork.Alongwiththeestablishmentofthenetwork,ahighlyprofessionalHIVclinicaltreatmentandresearchteamwasalsosetup.Lisaidthat“withthegrowingnumberofHIV-positivepeopleinChina,theteamwillplayamoresignificantrole.”ChinesestandardChinabeganitsresearchintogenericanti-AIDSdrugsin2002.However,itshomemadegenericdrugscausedseveresideeffects.LidecidedtodowhathecouldtooptimizeChina’sHIVtreatment.LifoundthatduetoChinesepeople’sdifferentconstitutions,thevolumesuggestedinothercountrieswastoomuch.Additionally,inChina,HepatitisCtendstoappearalongwithAIDS,somethingthatrarelyoccurredinothercountries.Intheinternationalcommunity,Favirenz(EFV)wasdesignedtocontain600milligramsinapill,andthatstandardhadbeenusedinEuropeanandAmericancountriesforthelastfewdecades.However,Chinesepeopletendedtosufferdizzinessandhyperlipidemiaaftertakingthemedicine.In2015,LifoundthatthevolumewastoomuchforChinesepeople,andthatamoresuitablecontentwas400mg.However,therewereonlyexistingproductionlinesavailablefor50mg,200mgand600mgpills.In2017,apharmaceuticalfactorybasedinShanghai,EastChina,decidedtohelpsolvetheproblembyintroducingaproductionlineof400mgEFV,andthemedicinewasapprovedatthebeginningof2018.Thediscoverymadeitintothetop10medicalsciencereportsinChinain2018.Sofarin2019,morethan50,000peoplehavetakenthemedicine.“Therewillbetensthousandsofpatientstakingthemedicineinthenearfutureunlessnewmedicineisdeveloped,”Lisaid.Zidovudinewasfoundtopreventbonemarrowformationsixmonthsaftertakingit,andStavudinecauseslipoatrophyuptooneandahalfyearslater.A“shiftingtherapy”wasthenproposed,inwhichpatientsaregivenZidovudineforfivemonthsbeforethesideeffectskickin,thenshifttoStavudine.Sixmonthslater,theygobacktothepreviousmedicine.Whilethetreatmenthadthesamepositiveeffect,thesideeffectsweredramaticallyreduced.Thetherapywasthenmadeavailableinthewholecountry,benefitingmorethan20,000people.“Withthesideeffectsbeingminimized,patientsaremorewillingtotakethetherapy,whichhelpstoprolongtheirlivesandimprovequalityoflife,”saidLi.Newmodel“NowthatthesurvivalproblemofHIV-positivepeoplehasbeensolved,medicalworkersshouldnowfocusonhowtogivethembetterlives,”saidLi.“AIDSpatientsshouldbetreatedlikenormalpatients.”IntheclinicofPUMCH’sinfectionsdepartment,agrowingnumberofAIDSpatientscometotreattheircomplications.“OneAIDSpatientneededacoronaryarterybypassgraftingsurgery,otherwise,hewouldhavediedsoon.Heturnedtothespecializedinfectionshospitalonlytobetoldtheywerenotcapableofdoingthesurgery,”LitoldtheGlobalTimes.“Ibeggedtheotherdepartmenttodothesurgeryformyfirstpatient,”saidLi.Thesurgeonwasscaredthefirsttime,andafteracceptingmorepatients,theybecameusedtoit,treatingAIDSpatientslikenormalones.InordertobringaboutnormalizedmanagementforHIVpatients,preparationsarebeingmadetosetupanationwideAIDScomplicationalliance.Thealliancewillserveasaplatformfortraining,cooperationandclinicalresearch.TheheadlineonGlobalTimesnewspaper:LeaseofLifeSource:GlobalTimes/People’sDaily
2019.12.02
